Evidence-Based Outcomes for Patients with Non-Small Cell Lung Cancer Undergoing Resection

VALERIE W. RUSCH; Valerie W. Rusch

doi:10.1055/s-2000-9406

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2000; 21(5): 433-442
DOI: 10.1055/s-2000-9406

Evidence-Based Outcomes for Patients with Non-Small Cell Lung Cancer Undergoing Resection

Valerie W. Rusch

Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

Abstract

ABSTRACT

Surgery plays a vital role in the management of Stages I-IIIa NSCLC. Careful patient selection and improved perioperative care now allow pulmonary resection to be performed with a very low morbidity and mortality even in older patients, or in patients undergoing pneumonectomy or extended operations. Most patients with Stage IIIb disease are not candidates for surgery, but resection can be curative for highly selected groups of patients with T4 tumors when these are not associated with nodal metastases. Surgery in conjunction with induction chemotherapy or chemoradiation has become a standard approach to the management of Stage IIIa (N2) disease and, in that setting, can be performed safely and effectively. The role of surgical resection in the treatment of NSCLC will undoubtedly continue to evolve as we gain a better understanding of the biology and multimodality therapy of this disease.

KEYWORD

Surgery for non-small cell lung cancer - evidence-based outcomes

Volltext

Referenzen

REFERENCES

1 Ginsberg R J, Hill L D, Eagan R T. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg . 1983; 86 654-658
2 Nagasaki F, Flehinger B J, Martini N. Complications of surgery in the treatment of carcinoma of the lung. Chest . 1982; 82 25-29
3 Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg . 1998; 115 70-73
4 Pagni S, Federico J A, Ponn R B. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg . 1997; 63 785-789
5 Grégoire J, Deslauriers J, Guojin L, Rouleau J. Indications, risks, and results of completion pneumonectomy. J Thorac Cardiovasc Surg . 1993; 105 918-924
6 Muysoms F E, de la Rivière B A, Defauw J J. Completion pneumonectomy: Analysis of operative mortality and survival. Ann Thorac Surg . 1998; 66 1165-1169
7 Deslauriers J, Ginsberg R J, Dubois P, Beaulieu M, Goldberg M, Piraux M. Current operative morbidity associated with elective surgical resection for lung cancer. Can J Surg . 1989; 32 335-339
8 Harpole Jr H D, Liptay M J, DeCamp Jr M M, Mentzer S J, Swanson S J, Sugarbaker D J. Prospective analysis of pneumonectomy: Risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg . 1996; 61 977-982
9 Duque J L, Ramos G, Castrodeza J. Early complications in surgical treatment of lung cancer: A prospective, multicenter study. Ann Thorac Surg . 1997; 63 944-950
10 Perez C A, Stanley K, Grundy G. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the Radiation Therapy Oncology Group. Cancer . 1982; 50 1091-1099
11 Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest . 1995; 108 1278-1282
12 Shields T W. The ``incomplete'' resection. Ann Thorac Surg . 1989; 47 487-488
13 Liewald F, Hatz R A, Dienemann H, Sunder-Plassmann L. Importance of microscopic residual disease at the bronchial margin after resection for non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg . 1992; 104 408-412
14 Kaiser L R, Fleshner P, Keller S, Martini N. Significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg . 1989; 47 265-269
15 Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg . 1988; 96 440-447
16 Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg . 1978; 76 833-839
17 Thomas P A, Piantadosi S, The Lung Cancer Study Group. Postoperative T1 N0 non-small cell lung cancer. J Thorac Cardiovasc Surg . 1987; 94 349-354
18 Gail M H, Eagan R T, Feld R. Prognostic factors in patients with resected stage I non- small cell lung cancer. A report from the Lung Cancer Study Group. Cancer . 1984; 54 1802-1813
19 Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg . 1995; 110 601-605
20 Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: Lobar or hilar nodes. J Thorac Cardiovasc Surg . 1994; 107 1398-1402
21 Martini N, Burt M E, Bains M S, McCormack P M, Rusch V W, Ginsberg R J. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg . 1992; 54 460-466
22 Thomas P, Rubinstein L, The Lung Cancer Study Group. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Ann Thorac Surg . 1990; 49 242-247
23 The Ludwig Lung Cancer Study Group. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. Ann Surg . 1987; 205 67-71
24 Sorensen J B, Olsen J E. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. J Thorac Cardiovasc Surg . 1989; 97 245-251
25 Albain K S, Crowley J J, LeBlanc M, Livingston R B. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol . 1991; 9 1618-1626
26 Mitsudomi T, Tateishi M, Oka T, Yano T, Ishida T, Sugimachi K. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann Thorac Surg . 1989; 48 639-642
27 Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg . 1998; 65 1405-1409
28 Bréchot J-M, Chevret S, Charpentier M-C. Blood vessel and lymphatic vesel invasion in resected non-small cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer . 1996; 78 2111-2118
29 Kessler R, Gasser B, Massard G. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg . 1996; 62 1489-1493
30 Izbicki J R, Passlick B, Hosch S B. Mode of spread in the early phase of lymphatic metastasis in non-small cell lung cancer: Significance of nodal micrometastasis. J Thorac Cardiovasc Surg . 1996; 112 623-630
31 Buhr J, Berghäuser K-H, Morr H, Dobroschke J, Ebner H J. Tumor cells in intraoperative pleural lavage. An indicator for the poor prognosis of bronchogenic carcinoma. Cancer . 1990; 65 1801-1804
32 Slebos R JC, Kibbelaar R E, Dalesio O. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med . 1990; 323 561-565
33 Rodenhuis S, Slebos R JC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res . 1992; 52 2665s-2669s
34 Pastorino U, Andreola S, Tagliabue E. Immunocytochemical markers in Stage I lung cancer: Relevance to prognosis. J Clin Oncol . 1997; 15 2858-2865
35 Kwiatkowski D J, Harpole Jr H D, Godleski J. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: Clinical implications. J Clin Oncol . 1998; 16 2468-2477
36 The Lung Cancer Study Group, Thomas Jr A P, Rubinstein L. Malignant disease appearing late after operation for T1 N0 non-small-cell lung cancer. J Thorac Cardiovasc Surg . 1993; 106 1053-1058
37 Yano T, Yokoyama H, Inoue T. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0 disease and pN2 disease. J Thorac Cardiovasc Surg . 1994; 108 680-683
38 Jensik R J, Faber L P, Kittle C F, Meng R L. Survival following resection for second primary bronchogenic carcinoma. J Thorac Cardiovasc Surg . 1981; 82 658-668
39 Deschamps C, Pairolero P C, Trastek V F, Payne W S. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg . 1990; 99 769-778
40 Martini N, Flehinger B J, Zaman M B, Beattie Jr J E. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg . 1983; 198 386-397
41 Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. The prognosis of surgically resected N2 non-small cell lung cancer: The importance of clinical N status. J Thorac Cardiovasc Surg . 1999; 118 145-153
42 Patterson G A, Piazza D, Pearson F G. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg . 1987; 43 155-159
43 McCaughan B C, Martini N, Bains M S, McCormack P M. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg . 1985; 89 836-841
44 Downey R J, Martini N, Rusch V W, Bains M S, Korst R J, Ginsberg R J. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg . 1999; 68 188-193
45 Pitz C CM, de la Rivière B A, Elbers H RJ, Westermann C JJ, van den Bosch M M J. Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement. Thorax . 1996; 51 846-850
46 Pairolero P C, Arnold P G. Chest wall tumors. Experience with 100 consecutive patients. J Thorac Cardiovasc Surg . 1985; 90 367-372
47 Albertucci M, DeMeester T R, Rothberg M, Hagen J A, Santoscoy R, Smyrk T C. Surgery and the management of peripheral lung tumors adherent to the parietal pleura. J Thorac Cardiovasc Surg . 1992; 103 8-13
48 Spaggiari L, Rusca M, Carbognani P, Solli P. Hemivertebrectomy for apical chest tumors: Is risk justified by the outcome?. Ann Thorac Surg . 1998; 65 1515-1517
49 Pancoast H K, Henry K. Pancoast describes superior pulmonary sulcus tumor. Surg Rounds . 1980; January 29-32
50 Shaw R R, Paulson D L, Kee Jr L J. Treatment of the superior sulcus tumor by irradiation followed by resection. Ann Surg . 1961; 7 29-40
51 Hagan M P, Choi N C, Mathisen D J, Wain J C, Wright C D, Grillo H C. Superior sulcus lung tumors: Impact of local control on survival. J Thorac Cardiovasc Surg . 1999; 117 1086-1094
52 Rusch V W, Parekh K R, Leon L. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg . 2000; 119 1147-1153
53 Paulson D L. Extended resection of bronchogenic carcinoma in the superior pulmonary sulcus. Surgical Rounds . 1980; January 10-21
54 Dartevelle P G, Chapelier A R, Macchiarini P. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg . 1993; 105 1025-1034
55 Spaggiari L, Pastorino U. Transmanubrial approach with antero-lateral thoracotomy for apical chest tumor. Ann Thorac Surg . 1999; 68 590-593
56 Bains M S, Ginsberg R J, Jones W G. The clamshell incision. An improved approach to bilateral pulmonary and mediastinal tumor. Ann Thorac Surg . 1994; 58 30-33
57 Martini N, Yellin A, Ginsberg R J. Management of non-small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg . 1994; 58 1447-1451
58 Nakahashi H, Yasumoto K, Ishida T. Results of surgical treatment of patients with T3 non-small cell lung cancer. Ann Thorac Surg . 1988; 46 178-181
59 Pitz C CM, de la Rivière B A, Elbers H RJ, Westermann C JJ, van den Bosch M J. Results of resection of T3 non-small cell lung cancer invading the mediastinum or main bronchus. Ann Thorac Surg . 1996; 62 1016-1020
60 Weksler B, Bains M, Burt M. Resection of lung cancer invading the diaphragm. J Thorac Cardiovasc Surg . 1997; 114 500-501
61 Faber L P, Jensik R J, Kittle C F. Results of sleeve lobectomy for bronchogenic carcinoma in 101 patients. Ann Thorac Surg . 1984; 37 279-285
62 Mehran R J, Deslauriers J, Piraus M, Beaulieu M, Guimont C, Brisson J. Survival related to nodal status after sleeve resection for lung cancer. J Thorac Cardiovasc Surg . 1994; 107 576-582
63 Suen H-C, Meyers B F, Guthrie T. Favorable results after sleeve lobectomy or bronchoplasty for bronchial malignancies. Ann Thorac Surg . 1999; 67 1557-1562
64 Deslauriers J, Jacques L F. Sleeve pneumonectomy. Chest Surg Clin North Am . 1995; 5 297-313
65 Mitchell J D, Mathisen D J, Wright C D. Clinical experience with carinal resection. J Thorac Cardiovasc Surg . 1999; 117 39-53
66 Klepetko W, Wisser W, Birsan T. T4 lung tumors with infiltration of the thoracic aorta: Is an operation reasonable?. Ann Thorac Surg . 1999; 67 340-344
67 Rendina E A, Venuta F, De Giacomo T. Induction chemotherapy for T4 centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg . 1999; 117 225-233
68 Albain K S, Rusch V W, Crowley J J. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group Phase II study 8805. J Clin Oncol . 1995; 13 1880-1892
69 Albain K, Rusch V, Crowley J. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group study 8805. Proc ASCO . 1999; 18 (Abstract) 467a
70 Eberhardt W, Wilke H, Stamatis G. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature results of a Phase II trial. J Clin Oncol . 1998; 16 622-634
71 The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected Stage II and Stage III epidermoid cancer of the lung. N Engl J Med . 1986; 315 1377-1381
72 Sawyer T E, Bonner J A, Gould P M. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carinoma with ipsilateral mediastinal lymph node involvement. Cancer . 1997; 80 1399-1408
73 Evans W K. Adjuvant chemotherapy: Results and perspectives. Lung Cancer . 1995; 12(suppl 1) S35-S45
74 Keller S M, Adak S, Wagner H. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIA non-small cell lung cancer: An intergroup trial (E3590). Proc ASCO . 1999; 18 (Abstract) 465a
75 Wada H, Hitomi S, Teramatsu T, The West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol . 1996; 14 1048-1054
76 Martini N, Kris M G, Flehinger B J. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg . 1993; 55 1365-1374
77 Rosell R, Gómez-Codina J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med . 1994; 330 153-158
78 Roth J A, Fossella F, Komaki R. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Nat Cancer Inst . 1994; 86 673-680
79 Rusch V W, Albain K S, Crowley J J. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg . 1993; 105 97-106
80 Rusch V W, Albain K S, Crowley J J. Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer. Ann Thorac Surg . 1994; 58 290-2951